← Back to all writing

The Sugar in the Blood

Diabetes, movement, food, and the reversal question your doctor may not raise.

The Sugar in the Blood

Why this article exists

Diabetes is one of the most heavily studied conditions in medicine — and one of the most poorly communicated. The average person hears “diabetes” and pictures one disease. There are at least six. The average person with Type 2 is told it's “progressive — manage it, take your pills, expect insulin eventually.” For a meaningful fraction of those people, that is no longer the whole story, and the evidence saying so has been in The Lancet and in later long-term follow-up [1], [2], [4].

The average person with Type 1 is sometimes told the opposite — that food only matters as a carb-counting problem — and then quietly discovers that meal composition, exercise timing, sleep, insulin delivery and glucose variability all matter [12], [16], [17], [25], [27]. This piece tries to put the science, the missed nuances, the patient experience, and the resources in one place.

By the end you should be able to tell the types apart, recognise the emergency signs that mean stop reading and call an ambulance, understand why movement is one of the most powerful drugs you'll never be prescribed, make sense of the remission conversation — and walk into your next appointment with the questions that change your care [9]-[15], [21]-[25].

If you are overwhelmed, start here

  • Know your type. If your story is atypical, ask about GAD antibodies and C-peptide [9], [18].
  • Know the emergency signs: vomiting, abdominal pain, deep breathing, fruity breath, confusion, severe thirst or severe weakness mean urgent care [21], [22].
  • Walk 10-15 minutes after your biggest meal today. The evidence is simple, cheap, and surprisingly strong [10], [11].
  • Ask whether remission is a reasonable goal if you have early Type 2; ask what support and medication changes would make that safe [1], [2], [4], [13], [14].
  • Do not change insulin, sulfonylureas or SGLT2 inhibitors without a clinician involved [9], [23], [24].

The story most patients live

For most people with Type 2, it starts as nothing. Maybe you're tired more often. Thirsty in a way that doesn't quite go away. You pee at night when you didn't used to. Your vision blurs for a week and then clears. A small cut takes too long to heal. Those are classic hyperglycemia clues, but many adults have diabetes or prediabetes long before the symptoms become obvious [9], [29], [30].

A blood test lands a result you weren't expecting: “pre-diabetes,” or “Type 2.” Your doctor is calm, almost casual. They hand you a pamphlet about eating less sugar, suggest you “try to lose some weight,” and start you on metformin. The message — sometimes spoken, sometimes between the lines — is: this is your life now. Another pill in a few years. Eventually, maybe, insulin.

For most people with Type 1, the story is the opposite — fast and brutal. A child or young adult is suddenly drinking gallons, urinating constantly, losing weight despite eating. Sometimes the diagnosis comes in an ER, in diabetic ketoacidosis: vomiting, deep panting breaths, a fruity smell on the breath, sliding toward unconsciousness [21], [22]. From that day on, life is insulin, finger-pricks or a sensor, and the constant arithmetic of food plus activity plus insulin plus sleep [9], [25], [27].

And then there's the third story, the one almost no one tells. A lean, otherwise healthy adult in their thirties or forties is diagnosed with “Type 2.” They follow the rules. Their numbers won't budge. Metformin doesn't really work. They lose weight they didn't want to lose. A year, two years, sometimes longer pass before someone finally tests for GAD antibodies and C-peptide and realises they actually have LADA — Type 1 in slow motion, often misdiagnosed because it initially looks adult-onset and partly responsive [18].

Each of those stories has, somewhere in it, a moment where the patient could have pushed harder, asked a different question, or known one more thing. This article is for that moment.

— the humanistic core of this piece

What diabetes actually is

For everyone

Every cell in your body runs on glucose. After you eat, glucose enters your bloodstream. To get out of the blood and into your cells, it needs a key called insulin, made by beta cells in your pancreas. Diabetes is what happens when that system breaks — either the key isn't being made, the locks have become resistant, the pancreas has been damaged, or a pregnancy/genetic/immune trigger has changed the rules [9], [18]-[20].

BLOODSTREAMGGGGGGGGGCELLINSULINSUGAR PILES UPLOCKED OUTTHE LOCK
Glucose can't enter many cells efficiently without insulin signalling. In diabetes the key may be missing, the lock may resist it, or both — so sugar piles up in the blood while tissues struggle to use fuel properly.Schematic · the insulin–glucose system

When glucose can't get into cells, two things happen at once: your blood sugar rises, and some tissues cannot access fuel normally. Over years, high glucose and glucose variability damage nerves, eyes, kidneys and blood vessels; that is why modern care looks at HbA1c, time in range, blood pressure, kidney markers, lipids, feet and eyes together [9], [24], [27], [28].

The types — and why the type matters most

  • Type 1An autoimmune disease: the immune system destroys your beta cells, so you make little or no insulin and need it from outside, for life. You cannot reverse Type 1 with diet — you can manage it beautifully, but you cannot replace missing insulin with broccoli [9], [16], [17].
  • Type 2Primarily insulin resistance layered on beta-cell stress — roughly 90-95% of diagnosed adult diabetes in the U.S. This is the type where food, weight and movement can do extraordinary things, including remission for many people, especially early after diagnosis [1], [2], [4], [29], [30].
  • LADA · 1.5Latent autoimmune diabetes in adults — Type 1 in slow motion. Looks like T2 at first, resists T2 treatment, and often progresses to insulin. GAD antibodies and C-peptide are the tests to discuss when the story is atypical [18].
  • gestationalAppears during pregnancy and often resolves after birth — but flags higher long-term risk of later Type 2 and needs follow-up, not a shrug [9].
  • MODYA rare set of genetic forms; some respond differently to standard T1/T2 treatment. A strong family pattern of young diagnoses, insulin independence, and non-obese presentation are clues worth asking about [19].
  • Type 3cPancreatogenic diabetes, caused by pancreas damage — pancreatitis, surgery, cystic fibrosis, hemochromatosis or pancreatic cancer. It is frequently misclassified as T2 and may need pancreas-specific management [20].

For the scientist

The deep mechanism of T2D was reframed by Professor Roy Taylor at Newcastle as the twin-cycle hypothesis: excess fat accumulates inside the liver and pancreas — not just around them. Liver insulin resistance drives chronic over-production of glucose, and pancreatic fat is associated with impaired beta-cell function. Lose enough of that organ fat — not just body weight, organ fat — and beta-cell function can recover in some people [3], [5].

The twin-cycle hypothesisLIVER FAT + PANCREAS FAT CAN FORM A FEEDBACK LOOPFATTY LIVERFATTY PANCREASEXTRA GLUCOSE + FAT EXPORTWEAKER INSULIN RESPONSEweightlossCAN BREAK IT
In the twin-cycle model, liver fat and pancreas fat reinforce each other: the liver exports more glucose and fat, while beta cells lose the ability to answer meals strongly. Enough sustained weight loss can break the loop in people whose beta cells can still recover.After Taylor et al. · twin-cycle and personal fat threshold

In T1D the story is immunological — autoimmune destruction of beta cells leads to absolute insulin need. None of that means dietary intervention reverses T1D; it doesn't. Food, sleep, movement, stress, CGM and insulin strategy still matter deeply, but they sit on top of insulin replacement rather than replacing it [9], [16], [17], [25]-[27].

Diabetes is no longer a “blood sugar disease” in any sophisticated model. It's a metabolic systems disease — and the blood sugar is the smoke, not the fire.

The alarm: when to act

This section is structured by urgency. Read all three levels — the first one is the difference between a hospital visit and a funeral.

Push for a diagnosis — or rethink your label — this week

  • Increased thirst and urination, especially at night
  • Unexplained weight loss, especially with normal or increased eating (a big T1 / LADA red flag)
  • Constant fatigue, blurred vision, slow-healing cuts, recurrent yeast infections
  • Numbness or tingling in the feet or hands
  • A family member with Type 1, Type 2, or another autoimmune disease
  • A child or young adult unusually thirsty, tired, and losing weight — get them tested this week

And if you already carry a “Type 2” label but you're lean, were under 50 at diagnosis, your oral medications barely move the numbers, you have another autoimmune disease, or you're losing weight you can't explain — ask explicitly: “Could this be LADA? Can we test GAD antibodies and C-peptide?” Naming it changes the conversation [18].

The self-advocacy script (use it every appointment)

  • 01 · the trend“What's my HbA1c trend over time, not just today's number?” Direction matters more than any single value, and HbA1c should be interpreted alongside hypoglycemia risk and daily patterns [9], [27].
  • 02 · the type“What's my actual diagnosis — Type 1, Type 2, LADA, MODY, Type 3c or something else — and how sure are we?” Especially if your story is atypical [9], [18]-[20].
  • 03 · remission“Is remission a realistic goal for me, and if so, what's the plan?” For early-diagnosis T2D this is now an evidence-based question, not a fringe one [1], [2], [4], [15].
  • 04 · a CGM“Could I try a continuous glucose monitor, even short-term?” Two weeks of your own data teaches more than any pamphlet, especially when paired with structured review [25], [27], [28].
  • 05 · the rest“What are my numbers for kidneys, eyes, feet, blood pressure and cholesterol?” Diabetes is managed by these too, not just sugar [4], [9], [24].
  • 06 · the plan B“What does my care plan look like if my numbers don't change?” Get the next two steps in writing.
  • 07 · a dietitian“Can I see a diabetes-trained dietitian, not just be handed a leaflet?” Nutrition therapy works best when it is individualized, medically coordinated, and culturally realistic [12], [13].

Movement is medicine

You have likely been told to “exercise more.” That advice is correct and useless. Here is the version your doctor probably won't give you — starting with the timing trick almost nobody mentions. For the broader movement philosophy behind this series, see Move or Fuse; for diabetes, timing is where the magic becomes measurable [10]-[12].

The post-meal walk

Glucose spikes after meals — postprandial spikes — are a major contributor to daily glucose exposure. A 10- to 15-minute brisk walk starting soon after a main meal can blunt those spikes. In a randomised crossover trial in people with T2D, three short post-meal walks outperformed one longer walk taken at another time for postprandial glycemic control [10].

Glucose after the same mealTARGET CEILINGsat after eating15-min walkMEAL+2 HOURS
The same meal, two days. Sitting after eating can send glucose higher and keep it there; a short walk soon after eating often flattens the curve because working muscles pull sugar from the blood through partly insulin-independent pathways.After Reynolds et al. · post-meal walking crossover trial [10]

The mechanism is elegant: contracting muscles pull glucose out of the bloodstream through pathways that do not rely entirely on insulin, so you're sweeping sugar out without needing the pancreas to do all the work. In one crossover study of people with T2D treated with basal insulin, post-meal walking produced glycemic effects comparable to one prandial insulin injection for the tested meals — useful, but not a reason to change insulin without medical direction [11].

Three walks of fifteen minutes. That's it. If you only act on one thing in this entire article, act on this.

— the single highest-leverage habit

The two other legs

  • resistance ×2/wkMuscle is your largest glucose sink — the more lean muscle you carry and use, the more buffer your metabolism has. Bodyweight squats, lunges, push-ups, kettlebells, weights. Any of it counts [12].
  • aerobic 150/wkWalking, cycling, swimming, hiking — anything that gets you breathing harder for half an hour, several times a week. Insulin sensitivity improves after activity, which is why consistency beats intensity [12].

The carbohydrate question

This is the part where lived patient experience and mainstream guidelines have often talked past each other — and where the evidence is finally mature enough to be useful. Low-carb is not the only road. Total diet replacement, Mediterranean-style patterns, energy restriction, medication-assisted weight loss, bariatric surgery, and structured low-carb can all belong in serious care. The question is which route is safe, sustainable, and medically supervised for you [1], [2], [4], [12]-[15], [24].

Three real stories

  • 1982 · New YorkRichard Bernstein, a Type 1 engineer showing early complications, bought his own glucose meter, measured obsessively, and cut carbs hard. His “Law of Small Numbers” — smaller carb loads, smaller insulin doses, smaller errors — remains influential, but the stronger published evidence for very-low-carb T1D is still limited and requires specialist supervision [16], [17].
  • 2011 · NewcastleRoy Taylor's Counterpoint/DiRECT line of work showed that major weight loss can reduce liver and pancreas fat and restore insulin secretion in early T2D. In DiRECT, 46% of intervention participants were in remission at one year, off glucose-lowering medication [1], [5].
  • 2012 · SouthportGP David Unwin's NHS practice evaluated a lower-carbohydrate programme over eight years. It is not an RCT, but it is clinically useful real-world evidence: drug-free remission was more likely with shorter diabetes duration, greater weight loss, and sustained engagement [6].
Drug-free remission of Type 2,by studyReTUNE · lower BMI70%Unwin · NHS cohort~50%DiRECT · 1 year46%% REACHING REMISSION, OFF ALL DIABETES MEDICATION
Remission is not a fringe outcome, but the percentages are not interchangeable. DiRECT, ReTUNE and Unwin studied different populations and protocols; the useful lesson is that weight loss, early disease duration and long-term support matter.Selected studies · DiRECT [1], ReTUNE [3], Unwin [6]

Remission evidence at a glance

  • DiRECTA primary-care RCT using total diet replacement and structured food reintroduction: 46% remission at one year; five-year follow-up showed remission can persist but maintenance is hard [1], [2].
  • ReTUNEA small mechanistic study in people with T2D and BMI under 27: 70% achieved remission after supervised weight-loss cycles, supporting the personal fat threshold idea [3].
  • UnwinA real-world general-practice evaluation of lower carbohydrate eating and weight loss: encouraging remission and prescribing-savings data, but not randomized [6].
  • VirtaA remote-care ketogenic intervention with sustained glycemic and medication improvements at five years; useful evidence, but commercial sponsorship and non-randomized design should be remembered [7], [8].
  • Look AHEADA large lifestyle trial shows remission is associated with better long-term kidney and cardiovascular outcomes, while also reminding us that remission rates depend heavily on support and who enters the study [15].

In one sentence

Carbohydrates usually raise blood glucose most directly; protein can raise it more slowly; fat can delay digestion and change later glucose curves. Less carbohydrate often means less glucose load and less medication or insulin needed, but the right pattern must fit medications, kidney health, lipid response, culture, budget, preferences and eating-disorder risk [12]-[14], [16], [17], [23], [24].

What the data really supports

+Where the evidence is strong
  • For Type 2, remission via significant weight loss is real and replicable, with strong RCT evidence from DiRECT. The mechanism appears tied to loss of liver and pancreatic fat and residual beta-cell recovery [1], [2], [5].
  • Lower-carbohydrate, very-low-carbohydrate and ketogenic eating can improve HbA1c and reduce medication burden for some people with T2D; evidence is strongest short-term and more mixed long-term, so support and follow-up matter [6]-[8], [13], [14].
  • Formula meal-replacements (DiRECT), structured lower-carb plates (Unwin), and remote ketogenic care (Virta) are different roads with different tradeoffs; none should be treated as magic [1], [6]-[8].
  • For Type 1, lower-carb approaches can reduce glycemic variability for some people, but the evidence base is smaller and the safety bar is higher because insulin, growth, hypoglycemia and DKA risk are involved [16], [17].
!Where to stay cautious
  • The hardest part is maintenance. Remission at one year is meaningful; years three, five and ten are the real test. The five-year DiRECT follow-up is hopeful but sobering [2].
  • Low-carb does not reverse or cure Type 1. You will always need insulin; the goal is better control, fewer swings, or lower doses. Cutting carbs without adjusting insulin can cause severe hypoglycemia [16], [17].
  • In LADA, diet can help control glucose, but autoimmune beta-cell failure may still progress. Do not let “I feel fine” delay insulin once testing and your team say it is time [18].
  • In children, pregnancy, kidney disease, frailty, eating-disorder history, SGLT2 inhibitor use, or insulin dependence, aggressive carb restriction or rapid weight loss needs specialist supervision [9], [12], [23], [24].

How to try low-carb safely, like a scientist

  • 01 · tell your teamIf you're on insulin, sulfonylureas or SGLT2 inhibitors, doses may need to change quickly as carbs drop — otherwise you risk hypoglycemia or DKA. This is not optional [9], [23], [24].
  • 02 · get a baselineHbA1c, fasting glucose, lipids, kidney function, blood pressure, weight, waist, medication list, and any history of hypos. You can't measure progress without a starting line [9], [24].
  • 03 · get a CGMEven two weeks of CGM data can show which meals spike you, when you go low, and whether post-meal walks work for your body. Pair it with clinician review [25], [27], [28].
  • 04 · pick one protocolDiRECT-style meal replacement, lower-carb plates, Mediterranean energy reduction, medication-assisted weight loss, or another plan your team supports. Commit long enough to learn; don't half-do three at once [1], [6], [13], [14], [24].
  • 05 · track & reviewWeekly weight or waist if appropriate, fasting glucose if useful, quarterly HbA1c early on, and CGM time-in-range when available. Watch quality of life too [4], [25], [27], [28].
  • 06 · de-prescribe with your doctorAs your numbers respond, reduce medications with your doctor — don't stop drugs on your own, and don't get left on drugs you no longer need. That's the whole point [4], [23], [24].

The four-legged stool

For ankylosing spondylitis the metaphor was a three-legged stool. Diabetes needs four — and a stool missing a leg is just a stick. If you are also reading the AS series, this article pairs with Treating Ankylosing Spondylitis in 2026, because inflammation, movement, fatigue and food habits often collide in real life.

DIAGNOSIS & MEDSMOVEMENTFOODSLEEP & DATApushing the disease backwards— underneath all four · SELF-ADVOCACY —
Diagnosis and medicine, movement, food, and sleep/data. None works alone. The leg most often missing is whichever one your appointment ran out of time to mention.Diagram · author's own
  • diagnosis & medsT1 needs insulin, always. T2 needs the lightest pharmaceutical toolkit that controls the disease — and modern options such as metformin, GLP-1/GIP-based medicines, GLP-1 receptor agonists and SGLT2 inhibitors can be powerful and organ-protective in the right person. Don't refuse medicine out of ideology; do question drugs you've outgrown [9], [24].
  • movementEvery day, on purpose. Post-meal walks first, resistance training twice a week, an aerobic base. Cheap, low-risk for most people, and useful in every type of diabetes when adapted safely [10]-[12].
  • food as a toolNot a punishment. Reduce the glucose load or energy surplus enough that your physiology can improve — for many T2 patients that means lower carbohydrate or lower energy intake in some sustainable form; for T1, smaller carb loads may mean smaller swings, but insulin remains non-negotiable [1], [13], [14], [16], [17].
  • sleep, stress, dataPoor sleep and stress can worsen glucose patterns; CGM turns vague advice into personal feedback. Treat all three as medical interventions, not lifestyle decoration [25]-[28].

The fourth leg: sleep and data

Sleep is not soft advice. In a systematic review and meta-analysis, both short and long sleep duration, and poorer sleep quality, were associated with worse HbA1c in people with Type 2 diabetes [26]. One bad night can make the next day look like a food failure when it is partly a sleep signal.

  • sleepAim for a repeatable sleep window before you chase perfect macros. If snoring, morning headaches, daytime sleepiness or resistant blood pressure are present, ask about sleep apnea; treating sleep disorders can make glucose management less chaotic [12], [26].
  • stressStress hormones can raise glucose and also drive the behaviours that raise glucose. The practical intervention is not “relax”; it is predictability: meals planned, medication available, walks scheduled, support visible [12].
  • CGMUse CGM as a pattern finder, not a shame machine. Look at time in range, time below range, overnight lows, post-meal peaks, and what happens after walks [25], [27], [28].
  • privacyData belongs to the patient. Before connecting an app, know who sees the readings, whether your clinician can review them, and whether alerts help you or make you anxious.

And running underneath all four: self-advocacy. The right diagnosis. The right type label. The right questions in the appointment. The willingness to say “I'd like to aim for remission” out loud if you have Type 2 and it fits your situation. The community that keeps you going on month nine, when it's hard [4], [12], [15].

That is the difference, over a lifetime with diabetes, between drifting toward complications and pushing the disease backwards.

The mini-directory

Real, working starting points across the spectrum — from peer-reviewed science to community support. Treat forums and social media as hypotheses to test with your medical team; treat trial papers, standards of care and clinical sites as stronger ground. Especially with insulin doses, SGLT2 inhibitors, pregnancy, children, kidney disease or rapid weight loss [9], [12], [23]-[25].

01
Key research & trialsRead these, or hand them to your doctor.
  • DiRECT — Lean, Taylor et al. (2018)Primary-care remission of T2D via total diet replacement · reference [1]
  • DiRECT 5-year results (2024)Durability and maintenance of remission · reference [2]
  • ReTUNERemission possible at lower BMIs in a small mechanistic study · reference [3]
  • Look AHEAD long-term outcomesRemission associated with lower kidney/cardiovascular risk · reference [15]
  • Unwin et al. NHS low-carb evaluationMulti-year general-practice cohort · reference [6]
  • LADA consensus statementRecognition, C-peptide categories and management · reference [18]
  • MODY and Type 3c referencesWhen the diagnosis does not behave like ordinary T1/T2 · references [19], [20]
  • Post-meal walking studiesReynolds and Suntornlohanakul · references [10], [11]
02
Trustworthy clinical referencesFor the search bar; for the doctor's office.
  • Mayo Clinic — DKA warning signsclinical emergency symptoms · reference [22]
  • CDC — DKAplain-language emergency explanation · reference [21]
  • Cleveland Clinic — LADAmy.clevelandclinic.org
  • ADA Standards of Care in DiabetesUpdated annually; 2026 sections cited here · references [9], [12], [24], [25]
03
Patient organizationsGuidelines, advocacy, education.
  • American Diabetes Association (ADA)Guidelines, advocacy, education · diabetes.org
  • Diabetes UKFunder of DiRECT · exceptional patient education
  • Breakthrough T1D (formerly JDRF)The major T1D org · TypeOneNation forum
  • Beyond Type 1Modern, patient-led T1D content, including LADA
  • Public Health Collaboration (UK)Unwin's network · low-carb resources
  • Virta HealthSupervised ketogenic T2D reversal program; useful but commercial
04
Forums, Reddit & FacebookThe lived-experience layer.
  • Reddit · r/diabetesThe largest general diabetes community
  • Reddit · r/diabetes_t1, r/diabetes_t2, r/LADAType-specific communities
  • Reddit · r/CGMMonitor users sharing graphs and learnings
  • Diabetes.co.uk ForumHuge UK community where Unwin's low-carb work took root
  • CGM in the Cloud / NightscoutDIY remote monitoring — invaluable for T1 parents
05
Low-carb & remission resourcesPlates, programs, recipes.
  • PHC “Real Food Lifestyle” guidesUnwin-style plates with carb-in-teaspoons-of-sugar visuals
  • Diabetes.co.uk Low Carb ProgramNHS-trusted structured program
  • DietDoctor.comExtensive low-carb / keto recipe & education library; verify medication safety with your clinician
06
BooksFor the patient who wants the source.
  • Roy Taylor — Life Without DiabetesThe science and the practical pathway
  • Richard Bernstein — Diabetes SolutionThe bible of low-carb T1D management
  • Gary Scheiner — Think Like a PancreasThe most-loved practical T1D self-management book
  • Unwin & Unwin — The Low-Carb Diabetes SolutionA step-by-step plan
07
Video & appsUse the platforms; pick the institutions.
  • YouTube · “Roy Taylor type 2 remission”Use as explanation; confirm claims against references [1]-[5]
  • YouTube · “Sarah Hallberg TEDx”A motivating low-carb talk; not a personalized protocol
  • MySugr / Glucose Buddy / OneDropLogging and pattern-finding; check privacy settings
  • Tidepool / Carb Manager / CronometerDevice data review & carb tracking; pair with clinician review

The story is no longer only one

For most of the last century, the dominant story of diabetes was managed decline — a slow accumulation of pills, then insulin, then complications. That story is no longer the only one available.

If you have Type 2 and you're newly diagnosed, the door is open: there is now serious, peer-reviewed evidence that early, supported weight loss — by whichever safe and sustainable route fits your life — can put diabetes into remission for some people. Ask for that conversation. Do not accept “progressive” as your only option until someone has talked through remission, medication safety, maintenance, and monitoring [1]-[8], [13]-[15].

If you have Type 1, the story is different but no less hopeful: with modern insulins, CGMs, pumps, automated delivery, lower-variability food strategies and a smart relationship with activity, your time-in-range can improve dramatically. You can't reverse Type 1. You can absolutely manage it with precision. And if you suspect LADA, MODY, Type 3c, or that your label is wrong — push. The right diagnosis is the prerequisite for the right life [9], [16]-[20], [25], [27].

If you only do three things

  • After your next main meal, walk for 10-15 minutes unless your clinician has told you not to [10]-[12].
  • Book or prepare for one appointment with the script above: type, trend, remission, CGM, kidneys/eyes/feet/blood pressure/lipids, medication plan, dietitian [4], [9], [18], [24], [25].
  • Make one two-week experiment boring enough to work: same breakfast, same sleep window, same post-meal walk, one food change at a time, and track what happens [25]-[28].

Walk after your meals. Lift something heavy twice a week. Sleep. Watch what you eat with curiosity, not shame. Find your community. Ask the next question.

— whatever your type
✻ · ✻

References

  1. M. E. J. Lean et al.. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial The Lancet (2018). Accessed: Jul. 9, 2026. [Online]. Available: https://doi.org/10.1016/S0140-6736(17)33102-1
  2. M. E. J. Lean et al.. 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK The Lancet Diabetes & Endocrinology (2024). Accessed: Jul. 9, 2026. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/38423026/
  3. R. Taylor et al.. Aetiology of Type 2 diabetes in people with a normal body mass index: testing the personal fat threshold hypothesis Clinical Science (2023). Accessed: Jul. 9, 2026. [Online]. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC10472166/
  4. M. C. Riddle et al.. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes Diabetes Care (2021). Accessed: Jul. 9, 2026. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/34462270/
  5. R. Taylor et al.. Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for Beta Cell Recovery Cell Metabolism (2018). Accessed: Jul. 9, 2026. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/30078554/
  6. D. Unwin et al.. What predicts drug-free type 2 diabetes remission? Insights from an 8-year general practice service evaluation of a lower carbohydrate diet with weight loss BMJ Nutrition, Prevention & Health (2023). Accessed: Jul. 9, 2026. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/37559961/
  7. A. L. McKenzie et al.. 5-Year effects of a novel continuous remote care model with carbohydrate-restricted nutrition therapy including nutritional ketosis in type 2 diabetes Diabetes Research and Clinical Practice (2024). Accessed: Jul. 9, 2026. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/39433217/
  8. S. J. Athinarayanan et al.. Long-term effects of a novel continuous remote care intervention including nutritional ketosis for the management of type 2 diabetes Frontiers in Endocrinology (2019). Accessed: Jul. 9, 2026. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/31231311/
  9. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026 Diabetes Care (2026). Accessed: Jul. 9, 2026. [Online]. Available: https://diabetesjournals.org/care/article/49/Supplement_1/S27/163926/2-Diagnosis-and-Classification-of-Diabetes
  10. A. N. Reynolds et al.. Advice to walk after meals is more effective for lowering postprandial glycaemia in type 2 diabetes mellitus Diabetologia (2016). Accessed: Jul. 9, 2026. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/27747394/
  11. O. Suntornlohanakul et al.. Glycemic effect of post-meal walking compared to one prandial insulin injection in type 2 diabetic patients treated with basal insulin Diabetes Research and Clinical Practice (2020). Accessed: Jul. 9, 2026. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/32236116/
  12. American Diabetes Association Professional Practice Committee. 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes-2026 Diabetes Care (2026). Accessed: Jul. 9, 2026. [Online]. Available: https://diabetesjournals.org/care/article/49/Supplement_1/S89/163932/5-Facilitating-Positive-Health-Behaviors-and-Well
  13. A. B. Evert et al.. Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report Diabetes Care (2019). Accessed: Jul. 9, 2026. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/31000505/
  14. J. Z. Goldenberg et al.. Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission The BMJ (2021). Accessed: Jul. 9, 2026. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/33441384/
  15. E. W. Gregg et al.. Impact of remission from type 2 diabetes on long-term health outcomes: findings from the Look AHEAD study Diabetologia (2024). Accessed: Jul. 9, 2026. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/38233592/
  16. B. S. Lennerz et al.. Management of Type 1 Diabetes With a Very Low-Carbohydrate Diet Pediatrics (2018). Accessed: Jul. 9, 2026. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/29735574/
  17. J. R. Turton et al.. Low-carbohydrate diets for type 1 diabetes mellitus: A systematic review PLOS ONE (2018). Accessed: Jul. 9, 2026. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/29596460/
  18. R. Buzzetti et al.. Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel Diabetes (2020). Accessed: Jul. 9, 2026. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/32847960/
  19. S. Naylor and A. T. Philipson. Maturity-Onset Diabetes of the Young Overview GeneReviews, NCBI Bookshelf (2024). Accessed: Jul. 9, 2026. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK500456/
  20. P. Woodmansey and E. McGovern. Type 3c: Understanding pancreatogenic diabetes Pancreas (2022). Accessed: Jul. 9, 2026. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/36219100/
  21. Centers for Disease Control and Prevention. Diabetic Ketoacidosis CDC (2024). Accessed: Jul. 9, 2026. [Online]. Available: https://www.cdc.gov/diabetes/about/diabetic-ketoacidosis.html
  22. Mayo Clinic Staff. Diabetic ketoacidosis: Symptoms and causes Mayo Clinic (2025). Accessed: Jul. 9, 2026. [Online]. Available: https://www.mayoclinic.org/diseases-conditions/diabetic-ketoacidosis/symptoms-causes/syc-20371551
  23. A. Musso et al.. Diabetic ketoacidosis with SGLT2 inhibitors The BMJ (2020). Accessed: Jul. 9, 2026. [Online]. Available: https://www.bmj.com/content/371/bmj.m4147
  24. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 Diabetes Care (2026). Accessed: Jul. 9, 2026. [Online]. Available: https://diabetesjournals.org/care/article/49/Supplement_1/S183/163934/9-Pharmacologic-Approaches-to-Glycemic-Treatment
  25. American Diabetes Association Professional Practice Committee. 7. Diabetes Technology: Standards of Care in Diabetes-2026 Diabetes Care (2026). Accessed: Jul. 9, 2026. [Online]. Available: https://diabetesjournals.org/care/article/49/Supplement_1/S150/163922/7-Diabetes-Technology-Standards-of-Care-in
  26. S. W. H. Lee, K. Y. Ng, and W. K. Chin. The impact of sleep amount and sleep quality on glycemic control in type 2 diabetes: A systematic review and meta-analysis Sleep Medicine Reviews (2017). Accessed: Jul. 9, 2026. [Online]. Available: https://doi.org/10.1016/j.smrv.2016.02.001
  27. T. Battelino et al.. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range Diabetes Care (2019). Accessed: Jul. 9, 2026. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/31177185/
  28. R. Raj et al.. Time in range, as measured by continuous glucose monitor, as a predictor of microvascular complications in type 2 diabetes BMJ Open Diabetes Research & Care (2022). Accessed: Jul. 9, 2026. [Online]. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC8724710/
  29. Centers for Disease Control and Prevention. National Diabetes Statistics Report United States Diabetes Surveillance System (2026). Accessed: Jul. 9, 2026. [Online]. Available: https://usdss.cdc.gov/diabetes/report.html
  30. Centers for Disease Control and Prevention. A Report Card: Diabetes in the United States CDC (2026). Accessed: Jul. 9, 2026. [Online]. Available: https://www.cdc.gov/diabetes/communication-resources/diabetes-statistics.html

Read like this, weekly.

The Letter — one handpicked piece, three small things worth your attention, and a reading list. Every Saturday, free.

Get the Letter
Keep reading
Ankylosing Spondylitis Starter Guide: Keeping the Devil Asleep
Health & Body

Ankylosing Spondylitis Starter Guide: Keeping the Devil Asleep

19 min read · 50 reads
Ankylosing Spondylitis: 11 Lessons Patients Learn From the AS Community
Health & Body

Ankylosing Spondylitis: 11 Lessons Patients Learn From the AS Community

27 min read · 24 reads
Move or Fuse: The Ankylosing Spondylitis Movement Guide
Health & Body

Move or Fuse: The Ankylosing Spondylitis Movement Guide

27 min read · 92 reads